Title:
5-PYRIDINE-1H-INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE
Document Type and Number:
WIPO Patent Application WO/2024/040768
Kind Code:
A1
Abstract:
Disclosed in the present invention are a 5-pyridine-1H-indazole compound, a pharmaceutical composition, and a use. The structure of the compound is represented by formula I or II, and also comprised are an isomer or pharmaceutically acceptable salt thereof, or a mixture of said isomer and salt. The compound and the pharmaceutical composition thereof can effectively inhibit the activity of CLK2 and DYRK1A proteins, can be used for preparing drugs for treating osteoarthritis, can show the efficacy at a molecular level, has a more excellent therapeutic effect, and optimally, can reach a nano-molar concentration level. In addition, a preparation method for the compound is simple, convenient and easy to operate.
Inventors:
LI ZHIYU (CN)
BIAN JINLEI (CN)
HU TIANXING (CN)
LIU MAI (CN)
SONG JIAXING (CN)
QIU ZHIXIA (CN)
WU HONGQIAN (CN)
XU XI (CN)
WANG JUBO (CN)
BIAN JINLEI (CN)
HU TIANXING (CN)
LIU MAI (CN)
SONG JIAXING (CN)
QIU ZHIXIA (CN)
WU HONGQIAN (CN)
XU XI (CN)
WANG JUBO (CN)
Application Number:
PCT/CN2022/133423
Publication Date:
February 29, 2024
Filing Date:
November 22, 2022
Export Citation:
Assignee:
UNIV CHINA PHARMA (CN)
International Classes:
C07D401/14; A61K31/416; A61K31/506; A61K31/517; A61K31/519; A61P19/02; A61P19/08; A61P21/00; A61P29/00; C07D213/16; C07D413/14; C07D471/04; C07D491/048; C07D495/04; C07F9/58; C07H19/048
Domestic Patent References:
| WO2012078777A1 | 2012-06-14 |
Foreign References:
| CN115353508A | 2022-11-18 | |||
| CN102595899A | 2012-07-18 | |||
| CN106032359A | 2016-10-19 | |||
| CN113164476A | 2021-07-23 | |||
| US20030199511A1 | 2003-10-23 | |||
| US20160009682A1 | 2016-01-14 | |||
| US20160009696A1 | 2016-01-14 |
Attorney, Agent or Firm:
NANJING SUGAO PATENT AND TRADEMARK FIRM ( ORDINARY PARTNERSHIP ) (CN)
Download PDF: